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Question: To develop clinical guidelines for
the management of cryptorchidism in pre-puber-
tal boys, from early diagnosis through therapy to
long-term follow-up and prognosis.
Method: Systematic review of articles from the
medical literature, referenced since 1966, using
validated search strategies through the following
databases: Medline, Cochrane Database of Sys-
tematic Reviews, Cochrane Register of Con-
trolled Trials, EMBASE, DARE, ACP Journal
Club, National Guidelines Clearinghouse,
Guidelines International Network.  Relevant arti-
cles published after 1988 were taken as the basis
for the statements. Each statement was graded on
the basis of the study design and on its method-
ological quality (GRADE approach).  A multidis-
ciplinary panel of local experts discussed and eval-
uated each statement on the strength of this evi-
dence.
Results: 28 statements based on the best avail-
able evidence were drafted. The experts agreed
with all but two statements, which were rated un-
certain.  
Conclusions: Cryptorchidism is best diagnosed
clinically, and treated by surgical orchiopexy at
age 6–12 months, without a routine biopsy. If no
testis is palpable, or if other signs of hypovirilisa-
tion such as hypospadias are present, the chromo-
somal sex and hormonal status must be assessed.
Laparoscopy is the best way of diagnosing and
managing intra-abdominal testes.
Key words: cryptorchidism; guidelines; evidence-
based medicine
Summary
Cryptorchidism, defined as the absence of at
least one testis in the scrotum [1], is a frequent
condition in the paediatric population. It affects
up to 9% of full-term newborns and up to 1.5%
of one-year-old boys [2], and may involve the use
of considerable medical and economic resources,
arguably to prevent its potential long-term com-
plications: cancer and impaired fertility. Unclear
definitions and conflicting results from the med-
ical literature make its management still a much-
debated issue [3, 4].
Practice guidelines based on a sound evi-
dence-based methodology are a tool proposed to
caregivers and their patients to help them make
proper decisions according to the best available
scientific evidence [5]. They have no coercive
value. They should address an issue with impor-
tant health implications and wide variability of
management and existing scientific data, all of
which criteria are fulfilled for cryptorchidism. 
Our aim was to obtain clinical practice guide-
lines on the management of cryptorchidism in
pre-pubertal boys, from early diagnosis through
therapy to long-term follow-up and prognosis. 
Introduction
No external 
financial support.
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A systematic review of the literature was conducted
using search strategies of English, French, German and
Italian published articles referenced in Medline between
1966 and March 2006. The search strategy is detailed in
Table 1. Similar searches were conducted in other data-
bases (EMBASE, Cochrane Register of Controlled Trials,
DARE, ACP Journal Club). In addition, we searched the
Cochrane Database of Systematic Reviews, the National
Guidelines Clearinghouse and the Guidelines Interna-
tional Network for systematic reviews and published
guidelines to be adapted, if any. Our initial goal was to
adapt existing guidelines to a proposed adaptation ap-
proach [6]. In the absence of such guidelines we decided
to develop them de novo. We thus based their develop-
ment on the systematic literature search described above.
Table 1 indicates the search strategy used in Medline
(Ovid), which was adapted for the other databases. Table
2 indicates the definitions we adopted. We first ruled out
irrelevant articles based on abstract reading. We arbitrar-
ily decided to keep only articles published after 1988,
making exceptions for milestone articles that had not
been included in more recent updates or reviews. The
management of retrieved references was performed with
the support of Reference Manager©. Each article was first
graded from I to V according to the level of evidence (I:
randomised controlled trial or systematic review thereof;
II: non-randomised, controlled trial; III: prospective co-
hort study; IV: retrospective (historical) or case-control
study; V: case series or experts’ opinion). In addition, we
used the GRADE approach to better evaluate the level of
evidence and the strength of recommendations, taking
the design and the quality of studies into consideration
[7]. The expected best type of design varied according to
the clinical question, e.g. a randomised controlled study
for treatment, a study of the evaluation of a diagnostic
test’s efficacy or a prospective cohort study to evaluate
prognosis. We also rated, but did not report, the quality
of randomised controlled trials (RCTs) using Jadad’s
score [8]. A series of statements was developed on the
basis of the articles retrieved. For each of them we re-
ported the quality of evidence and the strength of state-
ments. These guidelines do not address cryptorchidism
as part of a syndrome.
A panel of local experts met to discuss and rate these
statements, bearing the evidence in mind. The panel tried
to reach a consensus, if possible, but consensus was not
forced. The experts included 4 paediatric surgeons (PF,
BJM, PR, CG), one paediatrician (FC), one paediatric ra-
diologist (FG), one paediatric endocrinologist (GT), one
urologist (PJ) and one epidemiologist (BB). Using a mod-
ified Delphi technique [9], further adapted to be used for
the explicit rating of guideline statements [10], the ex-
perts formally rated each statement on a 1–9 scale (1 to-
tally disagree, 9 totally agree). We consolidated these re-
sults in three categories (agree, uncertain, disagree) based
on the median agreement score and the degree of agree-
ment between the experts. The median score was ascer-
tained for each statement. In the absence of discordance
(no more than 2 scores between 1–3 and no more than 2
scores between 7 and 9), the vote was considered to re-
flect agreement when the median score was more than 7,
uncertainty when between 4 and 6, and disagreement
when between 1 and 3.
Results and comments
We did not find existing guidelines covering the
same issues and thus had to to develop guidelines anew;
399 articles were considered relevant, analysed and
graded. The quality of evidence and the strength of the
statements are summarised in Table 3. The quality of evi-
dence did depend on the design of the study. Twenty-
eight  statements were developed. The experts agreed
with all but two statements, which were rated uncertain.
A more detailed description follows below, in various
paragraphs, according to the key topics structuring the
answers to the clinical questions about early diagnosis
and management of cryptorchidism.
After the end of our review process, Ritzén et al pub-
lished the Nordic consensus on treatment of unde-
scended testes, along with an update of the literature [11].
Methods
Epidemiology
The prevalence of cryptorchidism at birth is
2.5–9%, with marked geographic variations.
Prevalence at 3 months is 1–1.9% and 0.8–1.5%
at 18 months [12]. Bilateral presentation is found
in 10–20% of cases. An oft suggested increase in
prevalence in more recent times has not been
proven so far [13, 14]. In any event, it appears that
more orchidopexies are performed than expected
from prevalence data [15]. Risk factors include ge-
netic predisposition, pre-term birth, low birth
weight and prenatal exposure to hormonal disrup-
tors or tobacco in either the mother or the father
[16–19]. 
Risk to subsequent fertility
We decided to stress paternity studies against
sperm-count values, endocrinological and histo-
logical studies, since the latter represent only sur-
rogate endpoints (fertility potential). Sperm counts
and hormone levels of cryptorchid patients may
be altered. However, while abnormal laboratory
tests suggest impaired fertility, they scarcely cor-
relate with actual fatherhood in paternity studies
and show considerable overlap between cryp-
torchid patients and the normal population. The
lower norm for sperm concentration values set at
20 million/mL by the WHO should be treated
with caution, as this parameter alone  may not be a
reliable indicator of male fertility [1, 20–22]. 
Patients with untreated bilateral cryp-
torchidism have a very high risk of sterility (ab-
normal sperm count in 100%; no paternity studies
available). If the condition has been corrected the
risk falls to 38% in paternity studies. Age at treat-
ment has not been investigated in these studies.
Testis location before treatment has no impact on
fertility [23]. Paternity chances in patients with
treated unilateral cryptorchidism are almost nor-
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Table 1
Search strategy, as used in  Medline / Ovid.
CRYPTORCHIDISM
1. Cryptorchidism/
2. empty scrotum.tw
3. undescended test$.tw
4. maldescensus test$.tw
5. non-descended test$.tw
6. ectopic test$.tw
7. retractile test$.tw
8. cryptorchi$.tw
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. limit 9 to human
11. limit 10 to (english or french or german or spanish 
or italian)
GUIDELINES
12. guideline$.tw
13. guideline.pt
14. exp guidelines/
15. practice guideline$.tw
16. exp practice guidelines/
17. position statement$.tw
18. practice parameter$.tw
19. practice standard$.tw
20. consensus development conference.tw
21. consensus statement.tw
22. state-of-the-art conference.tw
23. recommendation$.tw
24. association$.tw
25. societ$.tw
26. societies/
27. societies medical/
28. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 
or 22 or 23 
29. 24 or 25 or 26 or 27
30. 23 and 29
31. 28 or 30
32. 11 and 31
DIAGNOSIS
33. 11 and diagnosis.tw
34. 11 and imaging.mp
35. 11 and sonography.mp
36. 11 and ultrasonography.mp
37. 11 and tomography.mp
38. 11 and scintigraphy.mp
39. 33 or 34 or 35 or 36 or 37 or 38
TREATMENT
40. cryptorchidism/th
41. cryptorchidism/su
42. 11 and treatment.mp
43. gonadorelin/
44. 11 and 43
45. gonadotropin
46. 11 and 45
47. 40 or 41
48. limit 47 to human
49. limit 48 to (english or french or german or italian or spanish)
50. 44 or 46 or 49
51. limit 50 to review articles
52. limit 50 to guideline
53. limit 50 to meta-analysis
54. limit 50 to multi-center study
55. limit 50 to randomized controlled trial
56. limit 50 to review, academic
PROGNOSIS
57. 11 and prognosis.mp
58. 11 and complication$.mp
PUBLICATION DESIGN
59. 11 and controlled clinical trial.tw
60. 11 and placebo.tw
61. 11 and random$.tw
62. 11 and meta-anal$.tw
63. 11 and double-blind method/
64. 11 and double blind.tw
Table 2
Definitions of terms used to characterise cryptorchidism
Cryptorchidism: Absence of at least one testicle in the scrotum
Gliding testis: A testicle that can be brought down into the
scrotum but does not stay there after release 
of the manipulation. 
Retractile testis: A testicle that comes to lie outside the scrotum
because of the cremaster traction
Ectopic testis: A really cryptorchid testis abnormally attached
to extra-scrotal structures by gubernacular 
remnants [52, 53] 
Ascending testis: A testicle previously described as intrascrotal 
and that comes to lie permanently outside the
scrotum, either primarily (abnormal involution
of the peritoneo-vaginal process) or secondarily
(post-surgery, trapped testis) [54–56].
mal. Infertility was found in 10% of these patients
vs. 6% in normal controls in paternity studies.
There are no studies comparing treated with un-
treated unilateral cryptorchidism, but unilaterally
absent testis or unilateral orchidectomy do not
alter paternity rates [24].
Younger age at surgery is correlated with
more favourable FSH and inhibin B levels later in
life; whether this has an impact on fertility is not
known, since early surgery has been advocated
only in recent years. However, histological
changes appear as early as 9 months of age, pro-
viding the rationale for early intervention in the
hope of preventing further damage or even cor-
recting these abnormalities [25].
Testicular growth is reportedly better if sur-
gery is performed at 9 months than if performed
at 3 years of age [26].
Risk for cancer incidence
The relative risk of testicular cancer in cryp-
torchid patients is about 5 times higher than in
the general population [27]. 10% of all testicular
malignancies are associated with cryptorchidism
[28]. If the condition is treated before 10 years of
age this risk may fall to almost normal [27], or at
least be reduced to twice the norm [29]. However,
seminoma, by far the most common type of can-
cer in cryptorchidism, has a survival rate of nearly
100% today, so that previous treatment of cryp-
torchidism has no impact on these patients’ sur-
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Table 3
Summary of statements for the diagnosis and clinical management of cryptorchidism: quality of evidence, opinion of panel
experts and strength of recommendations, where applicable.
Statement Quality of Strength of Opinion of panel 
evidence1 recommendations2 experts about statement3
Diagnosis
Cryptorchidism must be actively looked for at birth Very low Strong Agree
Cryptorchidism must be actively looked for during routine Very low Strong Agree
pediatric controls
Cryptorchidism is best diagnosed clinically Very low Strong Agree
Paraclinical examinations are not routinely needed Very low Strong Agree
Clinical examination is performed with the patient supine Very low Uncertain Agree
In case of doubt, the testes should be sought with the child Very low Uncertain Agree
sitting cross-legged
If no testis is palpable, genetic sex and hormonal status must Very low Strong Agree
be assessed
If cryptorchidism is associated with other signs of hypovirilisation Very low Strong Agree
such as hypospadias, genetic sex and hormonal status must be assessed
Laparoscopy is the best diagnostic approach to impalpable testes Very low Weak Agree
The findings must be recorded in the patient’s medical file Very low Strong Agree
Treatment
Spontaneous descent can be expected during the first semester of life High Strong Agree
Optimal age for medical or surgical intervention is 6 to 12 months Low Uncertain Agree
If the testis lies distal to the superficial inguinal pouch, treatment Low Uncertain Uncertain
with human chorionic gonadotrophin may be tried
If the testis lies distal to the superficial inguinal pouch, treatment Low Uncertain Uncertain
with LH-RH-analogues may be tried
Cryptorchidism should be treated by surgical orchidopexy Moderate Strong Agree
The operation should be performed by specialised paediatric teams Moderate Weak Agree
in order to minimize complications
The rationale for treatment between 6 and 12 months is based Low N/A Agree
on histological findings  and data supporting better testicular growth 
after early surgery
The rationale for treatment between 6 and 12 months is based Low N/A Agree
on the absence of augmented surgical risk in experienced hands
Routine biopsy is not needed Low Strong Agree
Follow-up: Fertility
In unilateral cryptorchidism paternity chances are close to those High N/A Agree
in the control population
In unilateral cryptorchidism sperm count abnormalities can High N/A Agree
be expected
In bilateral cryptorchidism impaired fertility must be expected High N/A Agree
In bilateral cryptorchidism not corrected by the time of puberty High N/A Agree
paternity chances are very low
Follow-up: Oncological risk
Testicular cancer risk in patients with cryptorchidism is 4–10 times High N/A Agree
higher than in the control population
Treatment performed before 10 years of age reduces the oncological High N/A Agree
risk to 1–2 times the norm
Testicular status should be periodically assessed by the physician Very low Uncertain Agree
throughout childhood in all patients with treated or untreated 
cryptorchidism
Adult patients with a history of cryptorchidism should be taught Very low Uncertain Agree
testicular self-palpation in order to discover any abnormality
Screening biopsy is not indicated Low Strong Agree
1 High / Moderate / Low / Very low
2 Strong / Weak / Uncertain / Rejected / Not Applicable (N/A) 
3 Agree / Uncertain / Disagree with statement 
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vival [30, 31]. Systematic biopsy is not needed to
detect malignant tissue or a pre-malignant condi-
tion.
Risk to psychosexual wellbeing
Many authors agree that a dystopic testis may
interfere with psychosexual well-being [1]. Sper-
marche comes later in cryptorchid patients, but
sexual activity, penis size, testosterone levels, im-
potency problems and masculine identity scores
are the same as in the general population [32, 33].
The literature on the role of orthotopic gonads in
neurotic disturbances is unfortunately very scant
[34]. 
Risk of testicular torsion
There is no evidence that cryptorchidism is
linked with increased occurrence of testicular tor-
sion, although the belief is widely held [35, 36].
Diagnosis
The diagnosis of cryptorchidism is clinical. It
should be performed by an experienced examiner
in a quiet environment, to minimize the effect of
the cremasteric reflex [31]. Spontaneous testicular
descent can be expected only before 6 months of
age [13, 32]. Retractile testes follow a completely
different clinical course and are the main factor to
consider in differential diagnosis of true cryp-
torchidism. Ascending testis accounts for a large
proportion of late diagnoses of cryptorchidism.
While some claim that pubertal testosterone pro-
duction allows spontaneous descent [33], others
object that histological changes and sperm count
values are those of true cryptorchidism and that
treatment is mandatory [34]. Testis location must
be recorded in the patient’s file in order to detect
testicular ascent. 
Bilaterally non-palpable testes or unilateral
cryptorchidism associated with hypospadias sug-
gest a disturbance of sexual differentiation and re-
quire endocrine and genetic work-up. To date, no
imaging technique for non-palpable testes has
proven superior to laparoscopy, which also allows
treatment if there is a testis. Contralateral testicu-
lar size cannot be used as a predictor of
monorchidism [35].
Gadolinum-enhanced MR fares best among
imaging modalities, with an accuracy of almost
100% on small series [36, 37]. However, imaging
would make sense only in ruling out the presence
of testicular tissue with potential for malignant
degeneration, which is not the case yet [38].
Treatment
True cryptorchidism is associated with testic-
ular cancer, infertility and psychological distress.
Correcting the condition before 10 years of age
brings the cancer risk down to normal. Treatment
in the second semester of life aims to prevent his-
tological changes and is not associated with more
complications in the hands of experienced paedi-
atric surgical teams than when performed later in
life [24]. There is, however, no proven effect on
fertility in this approach as compared with surgery
by two years of age, as previously recommended
[32, 45]. In one study, unilateral cryptorchid testes
operated on at 9 months grew better than non-
operated testicles in the control group [26] and
testicles operated on at 3 years of age [38]. 
Surgery is the cornerstone of treatment. In-
guinal or high scrotal approaches have been
largely used for palpable or even non-palpable
testes [47]. Laparoscopy has become standard
practice in the diagnosis and treatment of non-
palpable testes [48, 49].
The success rates of the various hormonal
treatments in eliciting testicular descent or as ad-
juvant or neo-adjuvant treatments are not consis-
tent enough to allow evidence-based recommen-
dations [50–54].
Complications
Surgical mortality is extremely rare, and mor-
bidity is lowest if specialist paediatric teams per-
form surgery. Complication rates are not higher
in children undergoing surgery before age 2 [55,
56]. The most troublesome complications include
injury to the vas deferens and testicular vessels. 
Follow-up
The surgeon should evaluate patients at 1, 6
and 12 months post-surgery. Routine biopsies are
not indicated. After puberty, any testicular modifi-
cation should be sought by formerly cryptorchid
patients through self-palpation [57]. Testicular
size is not a predictor of sperm concentration val-
ues or of paternity chances [26].
Discussion and conclusion
In the absence of existing clinical practice
guidelines available for adaptation we developed
them de novo. We conducted a systematic search of
the literature which allowed us to develop guide-
lines that include a series of statements, all of
them rated by a multidisciplinary panel of experts.
These statements offer evidence-based arguments
for the rational management of paediatric cryp-
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torchidism. These guidelines are subject to some
limitations, however. The level and quality of
available evidence was in general low or very low
with the exception of follow-up for fertility. A
local panel of experts who were also influenced by
the local context examined the proposed state-
ments; thus, these guidelines should not be ap-
plied without investigating whether they are valid
in another context or country. Updating of these
guidelines is not fully ensured due to the limited
resources available for this purpose in the pro-
ducer organisation.
We propose that cryptorchidism is best diag-
nosed clinically and treated by surgical orchi-
dopexy at the age of 6–12 months without routine
biopsy. If no testis is palpable, or if other signs of
hypovirilisation such as hypospadias are present,
chromosomal sex and hormonal status must be
assessed. Laparoscopy is the best way to diagnose
and manage intra-abdominal testes. Finally, we
urge researchers in this and related fields to im-
prove the quality of the research produced. 
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